

Lexaria Bioscience Corp.

08:13 11 Jul 2019

Lexaria Bioscience inks CBD license pact in US and Canada with Universal Hemp

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX), a drug delivery platform company, revealed Thursday that it has inked a definitive five-year pact through its subsidiary Lexaria Hemp Corp with Universal Hemp LLC.

The Kelowna, British Columbia company will provide its patented DehydraTECH™ technology to Universal Hemp LLC, a manufacturer of hemp-based raw ingredients and CBD derivatives.

Universal Hemp plans to make its CBD-infused bulk food ingredients available in the US immediately, and in Canada when new legislation takes effect in October.

READ: Lexaria Bioscience inks CBD beverage license agreement in US with Nic's Beverages

The company did not disclose financial details, or royalty payment rates, although it did say that the companies have agreed to disclose minimum payments over the life of the agreement of US\$3,750,000.

"We are very excited about signing this licensing agreement with Lexaria Bioscience to bring to market Lexaria's highly effective delivery system which makes cannabidiol or hemp-derived CBD readily available in the human body," said Universal Hemp founder CEO Chad Kahunahana.

Tech being applied to CBD at scale

Kahunahana noted that Lexaria's technology was developed over many years for specified applications and is now, for the first time, being applied to CBD at scale.

"We anticipate our SuperBio Infusion line of ingredients will become the industry leader for CBD-infused health and beauty, food and beverage, wellness, athletic and other products where maximum performance is vital," said Kahunahana. "In terms of bioavailability, shelf stability and taste this is the best performing technology in the market, hands down. Our corporate customers cannot wait to put our water-soluble solution into their products."

DehydraTECH-enabled food ingredients are protected under Lexaria's existing US patents and include CBD-infused wheat or corn flour, gum Arabic, whey protein, green tea, tapioca starch and many forms suitable for beverage and dietary supplement formulations.


Lexaria Bioscience has 40 patents pending around the world for disruptive drug delivery technologies. A patent for DehydraTECH, which improves the taste, smell, speed and absorption of compounds, has been granted in the US and Australia.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-

Price: 0.255

Market Cap: \$22.96 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	0.99	0.22

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

inflammatory drugs, nicotine and other molecules.

"We are pleased to announce our new licensee Universal Hemp whose well respected presence in the hemp industry will enable our patented technology to have widespread use and distribution in high-performance products providing precision dosing, maximum strength, and rapid uptake," said Lexaria Bioscience CEO Chris Bunka.

Universal Hemp plans to make its CBD-infused bulk food ingredients available in the US immediately, and in Canada when regulations permit.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).